FDA Approves Erzofri for the Treatment of Schizophrenia and Schizoaffective Disorder
July 28, 2024FDA Warns Against Purchasing or Using Chemical Peel Skin Products Without Professional Supervision
July 30, 2024July 29, 2024 - Alpha Cognition has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Zunveyl (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease.
- Zunveyl, a novel oral therapy, has a dual mechanism of action designed to eliminate drug absorption in the GI tract, potentially addressing certain tolerability issues with leading AD medications, combined with the efficacy and long-term benefit profile of galantamine.
Source: Alpha Cognition